UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 1997
or
[ ] TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
----------- -----------
Commission File Number: 0-26082
VIDAMED, INC.
(exact name of registrant as specified in its charter)
Delaware 77-0314454
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
46107 Landing Parkway
Fremont, CA 94538
(Address of principal executive offices)
(510) 492-4900
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. [ X ] Yes [ ] No
The number of outstanding shares of the registrant's Common Stock, $.001 par
value, was 15,203,173 as of November 13, 1997.
Page 1 of 16
Exhibit Index at Page 15
<PAGE>
VIDAMED, INC.
INDEX
PART I: FINANCIAL INFORMATION
Page
Item 1. Condensed consolidated financial statements - unaudited
Condensed consolidated balance sheets - September 30, 1997
and December 31, 1996 3
Condensed consolidated statements of operations - three months
ended September 30, 1997 and 1996 and nine months ended
September 30, 1997 and 1996 4
Condensed consolidated statements of cash flows - nine months
ended September 30, 1997 and 1996 5
Notes to condensed consolidated financial statements 6
Item 2. Management's discussion and analysis of financial condition
and results of operations 8
PART II: OTHER INFORMATION
Item 1. Legal Proceedings 12
Item 2. Changes in Securities 12
Item 3. Defaults Upon Senior Securities 12
Item 4. Submission of Matters to a Vote of Security Holders 12
Item 5. Other Information 12
Item 6. Exhibits and Reports on Form 8-K 12
Signatures 13
Page 2 of 16
<PAGE>
PART I: FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
VidaMed, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
September 30, December 31,
1997 1996
------------ ------------
(Unaudited) (*)
Assets
Current Assets:
Cash and cash equivalents .......................... $ 13,517 3,879
Short-term investments ............................. -- 1,976
Accounts receivable ................................ 3,357 2,413
Inventory .......................................... 1,604 1,447
Other current assets ............................... 1,021 665
-------- --------
Total current assets ......................... 19,499 10,380
Property and equipment, net ........................ 3,470 2,259
Other assets, net .................................. 231 208
-------- --------
Total assets ................................. $ 23,200 $ 12,847
======== ========
Liabilities and stockholders' equity
Current liabilities:
Notes payable, current portion ..................... $ 757 $ 1,064
Accounts payable ................................... 2,187 1,246
Accrued professional fees .......................... 590 498
Accrued clinical trial costs ....................... 668 982
Accrued and other liabilities ...................... 3,397 3,114
Restructuring Accrual .............................. 2,100 --
Current portion of obligations under capital leases 173 470
Deferred revenue, current portion .................. 415 467
-------- --------
Total current liabilities .................... 10,287 7,841
Notes payable, noncurrent .......................... -- 480
Other long-term liabilities ........................ 666 825
Stockholders' equity:
Capital stock ...................................... 77,478 55,577
Accumulated deficit ................................ (65,231) (51,876)
-------- --------
Total stockholders' equity ................... 12,247 3,701
-------- --------
Total liabilities and stockholders' equity ... $ 23,200 $ 12,847
======== ========
* The Balance Sheet at December 31, 1996 has been derived from the audited
financial statements at that date but does not include all of the information
and footnotes required by generally accepted accounting principles for complete
financial statements.
See accompanying notes.
Page 3 of 16
<PAGE>
<TABLE>
VidaMed, Inc.
Condensed Consolidated Statements of Operations
(In thousands except per share amounts)
(Unaudited)
<CAPTION>
Three Months Ended Nine Months Ended
September 30, September 30,
--------------------- --------------------
1997 1996 1997 1996
-------- -------- -------- --------
<S> <C> <C> <C> <C>
Revenues:
Product sales, net ................... $ 1,809 $ 245 $ 7,164 $ 1,235
License fees and grant revenue ....... 550 50 650 150
-------- -------- -------- --------
Net revenues ......................... 2,359 295 7,814 1,385
Cost of Products Sold (see Note 5) ........ 3,306 709 6,354 2,331
-------- -------- -------- --------
Gross Profit (Loss) ....................... (947) (414) 1,460 (946)
Operating Expenses:
Research and development ............. 1,218 1,249 4,571 3,999
Selling, general and administrative .. 2,935 1,891 10,159 5,502
-------- -------- -------- --------
Total operating expenses ............. 4,153 3,140 14,730 9,501
-------- -------- -------- --------
Loss from operations ................. (5,100) (3,554) (13,270) (10,447)
Other income(expense), net ................ 23 10 (86) 19
-------- -------- -------- --------
Net loss .................................. $ (5,077) $ (3,544) $(13,356) $(10,428)
======== ======== ======== ========
Net loss per share ........................ $ (.39) $ (.33) $ (1.11) $ (1.02)
======== ======== ======== ========
Shares used in computing net loss per share 12,901 10,854 11,981 10,208
======== ======== ======== ========
Page 4 of 16
</TABLE>
<PAGE>
See accompanying notes.
VidaMed, Inc.
Condensed Consolidated Statement of Cash Flows
(In thousands)
(Unaudited)
Nine Months Ended
September 30,
--------------------
1997 1996
-------- --------
Cash flows from operating activities:
Net loss ......................................... $(13,356) $(10,428)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization .............. 907 1,063
Other ...................................... 146
Changes in assets and liabilities:
Accounts Receivable .................... (944) (183)
Inventory .............................. (157) (292)
Other current assets ................... (356) (104)
Other assets ........................... (23) 20
Accounts payable ....................... 941 145
Accrued and other liabilities .......... 2,088 523
Deferred revenue ....................... (52) (262)
-------- --------
Net cash used in operating activities ................. (10,952) (9,372)
-------- --------
Cash flows from investing activities:
Expenditures for property and equipment .......... (2,045) (584)
Purchases of short-term investments .............. -- (9,816)
Proceeds from maturities of short-term investments 1,977 15,667
-------- --------
Net cash (used in) provided by investing activities ... (68) 5,267
-------- --------
Cash flows from financing activities:
Net cash proceeds from issuance of Common Stock .. 21,828 554
Principal payments under capital leases .......... (380) (519)
Principal payments of long-term debt ............. (3) (18)
Principal payments of notes payable .............. (787) (3,402)
Net proceeds from issuance of notes payable
and convertible notes ........................ -- 9,776
-------- --------
Net cash provided by financing activities ............. 20,658 6,391
-------- --------
Net increase in cash and cash equivalents ............. 9,638 2,286
Cash and cash equivalents at the beginning
of the period ....................................... 3,879 5,687
-------- --------
Cash and cash equivalents at the end of the period .... $ 13,517 $ 7,973
======== ========
See accompanying notes.
Page 5 of 16
<PAGE>
VIDAMED, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 1997
(Unaudited)
1. Basis of presentation
The accompanying unaudited condensed consolidated financial statements of
VidaMed, Inc. (the "Company" or "VidaMed") have been prepared in accordance with
generally accepted accounting principles for interim financial information and
with the instructions for Form 10-Q and Article 10 of Regulation S-X. The
balance sheet as of September 30, 1997 and the statements of operations for the
three and nine months ended September 30, 1997 and 1996, and the statements of
cash flows for the nine months ended September 30, 1997 and 1996, are unaudited
but include all adjustments (consisting of normal recurring adjustments) which
the Company considers necessary for a fair presentation of the financial
position at such dates and the operating results and cash flows for those
periods. Although the Company believes that the disclosures in these financial
statements are adequate to make the information presented not misleading,
certain information normally included in financial statements and related
footnotes prepared in accordance with generally accepted accounting principles
have been condensed or omitted pursuant to the rules and regulations of the
Securities and Exchange Commission. The accompanying financial statements should
be read in conjunction with the financial statements and notes thereto included
in the Company's annual report on Form 10-K for the year ended December 31, 1996
filed with the Securities and Exchange Commission.
Results for any interim period are not necessarily indicative of results for any
other interim period or for the entire year.
2. Net loss per share
Net loss per share is computed using the weighted average number of shares of
common stock outstanding during the periods presented. Common equivalent shares
are excluded from the computation as their effect is anti-dilutive. In February
1997, the Financial Accounting Standards Board issued Statement No. 128,
Earnings per Share, which is required to be adopted on December 31, 1997. At
that time, the Company will be required to change the method currently used to
compute loss per share and to restate all prior periods. Under the new
requirements for calculating primary earnings per share or "basic" earnings per
share the dilutive effect of stock options will be excluded. The impact of
Statement 128 on the calculation of loss per share for the company is not
expected to be material.
3. Inventories
Inventories are stated at the lower of cost (determined using the first-in,
first-out method) or market value. Inventories at September 30, 1997 and
December 31, 1996 consist of the following:
September 30, December 31,
1997 1996
------------ -----------
Raw materials $ 358,000 $ 600,000
Work in process 57,000 174,000
Finished goods 1,189,000 673,000
------------ -----------
$1,604,000 $1,447,000
============ ===========
Page 6 of 16
<PAGE>
4. Common stock
In February 1997, the Company entered into an equity financing agreement with a
European investment bank under which provided the Company with the option to
sell to such investment bank up to $10.0 million of VidaMed common stock in
increments of up to $2.5 million. Under this arrangement, the common stock was
priced at a 10% discount to the current market price at the time of sale,
subject to adjustment based on a formula linked to the market price of the
Company's common stock during the 21 trading days following the sale. Concurrent
with each common stock issuance under this arrangement, the Company issued to
the investment bank a warrant to purchase one share of common stock for each 10
shares of common stock purchased under the arrangement. The exercise price of
the warrant is equal to the adjusted purchase price for the common stock
multiplied by 1/0.9, with the resulting product multiplied by 1.25. Each warrant
has a term of three years from the date of issuance.
As of September 30, 1997 the Company had issued 1,570,463 shares of common stock
under the arrangement, resulting in approximately $10 million of net proceeds.
In September 1997, the Company completed a private placement with certain
investors. In this transaction, the Company issued 2.6 million shares of Common
Stock at a purchase price of $4.75 per share resulting in net proceeds of $11.7
million to the Company. In connection with this financing, the Company issued
warrants to purchase an aggregate of 629,000 shares of Common Stock at an
exercise price of $6.33 per share.
5. Restructuring Accrual
In September 1997, VidaMed announced a restructuring program designed to reduce
costs and improve operating efficiencies by closing the company's U.K.
manufacturing facility. The Company anticipates that following a short
transition period, all future manufacturing of the VidaMed TUNA(R) System hand
pieces will occur in the U.S. In this regard, the Company moved into its new
headquarter facility in Fremont, California in July, 1997. The facility is
approximately 35,000 square feet and provides the necessary capacity to
manufacture the VidaMed TUNA hand piece. The company is currently qualifying the
facility as a FDA, GMP and ISO9001 site. A $2.1 million charge for the three and
nine months ended September 30, 1997 is reflected in cost of goods sold in the
Statements of Operations. The charge reflects $390,000 for the estimated loss on
the abandonment of fixed assets, a $1,305,000 charge for the Company's
obligation related to the shut down of the facility in the next six months and a
$405,000 obligation related to a grant.
The elements of the total charge as of September 30, 1997 are as follows (in
thousands):
Representing
----------------------------------------------------
Cash Outlays
------------------------
Total Asset
Charges Write-down Completed Future
Fixed assets $ 390 $ 390 $ -- $ --
Facility shut down 1,305 -- -- 1,305
Grant 405 -- -- 405
------ ------ ------- ------
Total Special Charges $2,100 $ 390 $ -- $1,710
====== ====== ======= ======
Page 7 of 16
<PAGE>
ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Management's Discussion and Analysis of Financial Condition and Results of
Operations for the three and nine months ended September 30, 1997 and 1996,
should be read in conjunction with the Management's Discussion and Analysis of
Financial Condition and Results of Operations included in the Company's Annual
Report on Form 10-K for the year ended December 31, 1996.
This Management's Discussion and Analysis of Financial Condition and Results of
Operations contains forward-looking statements which involve risks and
uncertainties. The Company's actual results may differ significantly from those
anticipated by the forward-looking statements. Factors that might cause such a
difference include, but are not limited to, those discussed below and in the
Company's Annual Report on Form 10-K for the year ended December 31, 1996.
Overview
VidaMed has a limited history of operations and has experienced significant
operating losses since its inception. As of September 30, 1997, the Company had
an accumulated deficit of $65.2 million. The Company commenced international
sales of its TransUrethral Needle Ablation ("TUNA") system in late 1993 and
United States sales in October 1996. Revenues for the quarters ended September
30, 1997 and 1996 include license fees for distribution rights in Japan.
VidaMed anticipates that a substantial amount of its revenues from product sales
in the future will be from sales in the United States. The Company filed a
premarket 510(k) notification with the Food and Drug Administration ("FDA") for
the VidaMed TUNA System in March 1996. The company received FDA clearance to
market this system for the treatment of symptoms associated with benign
prostatic hyperplasia (BPH) in the United States on October 8, 1996. The Company
applied to the American Medical Association for a current procedure terminology
("CPT") code covering the TUNA Procedure. A CPT code relating to the TUNA
Procedure has been published in the Federal Register and will be part of the
Medicare Physician Fee Schedule for calendar 1998. Although the 1998 CPT code
facilitates Medicare reimbursement within established reimbursement amounts,
there can be no assurance of Medicare reimbursement as claims are submitted on
an individual basis for reimbursement consideration. In particular, individual
Medicare directors in each state will be responsible for making determinations
regarding reimbursement for the TUNA Procedures, and there can be no assurance
as to the extent to which Medicare will reimburse for the TUNA Procedures. In
the United States, the Company markets the VidaMed TUNA System through a network
of five VidaMed sales managers and approximately 35 independent dealers and
representatives. A network of distributors, supported by VidaMed staff, cover
other countries in Europe, Asia and South America.
VidaMed does not anticipate reaching profitability in the near future. The
Company expects its operating losses to continue through at least the next four
quarters as it continues to expend substantial resources in expansion of
marketing and sales activities, funding clinical trials in support of regulatory
and reimbursement approvals, and research and development. The Company's future
profitability will be
Page 8 of 16
<PAGE>
dependent upon, among other factors, market acceptance of the VidaMed TUNA
Procedure and availability of third-party reimbursement for procedures performed
with the TUNA System.
Although the Company has received FDA clearance of its 510(k) notification for
the TUNA System for treatment of symptoms associated with BPH and has commenced
marketing of the TUNA System in the United States, there can be no assurance
that the TUNA System will be deemed clinically or cost effective by many health
care providers and payors, will be deemed superior to other current and emerging
methods for treating BPH or will achieve significant market acceptance in the
United States market. As of September 30, 1997 there have been approximately 200
RF generators sold in the United States and over 2,500 TUNA procedures performed
by urologists. Furthermore, determinations of reimbursement of the VidaMed TUNA
Procedure by private and governmental health payors are made by such payors and
their medical directors independently of the FDA approval, and, accordingly,
there can be no assurance that the TUNA Procedure will be generally reimbursed
at adequate levels in the United States under either private or governmental
healthcare payment systems. Availability of Medicare reimbursement for the TUNA
Procedure may be dependent on publication of clinical data relating to the
cost-effectiveness and duration of the TUNA therapy. Adequacy of reimbursement
for TUNA procedures could have an adverse effect on the ability of the TUNA
System to achieve market acceptance. Failure of the TUNA Procedure to achieve
market acceptance in the United States would have a material adverse effect on
business, financial condition and results of operations of the Company.
The Company does not have a backlog of orders for its products in countries
where the VidaMed TUNA System is sold and anticipates that it will continue to
manufacture and ship orders after their receipt. Accordingly, the Company does
not anticipate that it will develop a significant backlog in the future.
Results of Operations
Net revenues for the three months ended September 30, 1997 increased 700% to
$2,359,000 from $295,000 in the three months ended September 30, 1996. Product
sales in the third quarter of 1997 increased 638% to $1,809,000 from $245,000 in
the same period in 1996. For the first nine months of 1997 net revenues
increased 464% to $7,814,000 from $1,385,000 during the same period in 1996.
Product sales for the first nine months of 1997 increased 480% to $7,164,000
from $1,235,000 during the same period in 1996. The increase in net revenues and
product sales between 1997 and 1996 is the result of sales of the VidaMed TUNA
System in the United States and a one time license fee from VidaMed's Japanese
distributor as a result of clearance of the VidaMed TUNA System for sale in
Japan. The system was approved for sale in the U.S. in October 1996.
Cost of product sold for the three and nine months ended September 30, 1997
includes a one time charge of $2.1 million related to the shut down of VidaMed's
U.K. facility. Excluding the $2.1 million charge, cost of product sales
increased 70% to $1,206,000 in the three months ended September 30, 1997 from
$709,000 in the three months ended September 30, 1996. Excluding the $2.1
million charge, for the nine months ended September 30, 1997 cost of product
sales increased 82% to $4,254,000 from $2,331,000 in the same period in 1996.
The increase is due to higher product sales in the first nine months of 1997.
Increased sales in the first nine months of 1997 resulted in improved absorption
of manufacturing overhead.
Research and development expenses decreased 2% to $1,218,000 in the three months
ended September 30, 1997 from $1,249,000 in the three months ended September 30,
1996. The decrease is primarily due to the completion in the second quarter,
ended June 30, 1997 of the development efforts on both the VidaMed
Page 9 of 16
<PAGE>
TUNA System RF generator and VidaMed TUNA System handpiece. For the nine months
ended September 30, 1997 research and development expenses increased 14% to
$4,571,000 from $3,999,000 in the same period of 1996. The increase was
primarily due to product development for the new VidaMed TUNA System RF
generator resulting from increased outside services and development material
which occurred in the first quarter of 1997.
Selling, general and administrative expenses increased 55% to $2,935,000 in the
three months ended September 30, 1997 from $1,891,000 in the three months ended
September 30, 1996. For the nine months ended September 30, 1997 selling,
general and administrative expenses increased 85% to 10,159,000 from $5,502,000
in the same period in 1996. The increase was primarily due to increased sales
and marketing expense incurred in the continuing product introduction of the
VidaMed TUNA System in the United States. Significant sales and marketing
expenses included commissions, advertising expenses, trade shows and physician
workshops.
Total operating expenses in the three months ended September 30, 1997 increased
32% to $4,153,000 from $3,140,000 in the three months ended September 30, 1996.
Total operating expenses for the first nine months of 1997 increased 55% to
$14,730,000 from $9,501,000 in the same periods in 1996. The increase in
operating expenses was due primarily to the increase in selling, general and
administrative expenses.
Other income (expense) for the three months ended September 30, 1997 was $23,000
and other expense for the nine months ended September 30, 1997 was $86,000,
compared to other income of $10,000 and $19,000 for the comparable periods in
1996. This change is primarily due to lower interest income attributable to
lower investment balances, offset in part by lower interest expense due to
decreasing notes payable and capital lease balances.
The net loss for the three and nine month periods ended September 30, 1997 was
$5,077,000 and $13,356,000, respectively, compared to $3,544,000 and $10,428,000
for the comparable periods in 1996.
Liquidity and Capital Resources
At September 30, 1997 the Company's cash and cash equivalents were $13,517,000,
compared to $5,855,000 at December 31, 1996. In February 1997, the Company
entered into an equity financing agreement with a European investment bank under
which the Company may, at its option, sell to such investment bank up to $10.0
million of VidaMed common stock. As of September 30, 1997 the Company has
completed this agreement. In September 1997, the Company issued common stock in
a private placement with certain investors. Approximately 2.6 million shares of
VidaMed common stock were issued in September for approximately $11.7 million in
net proceeds.
In April 1995, the Company obtained a $3,000,000 credit facility secured by
VLLI. To date, the Company has borrowed $3,000,000 under this facility.
Borrowings bear interest at the prime rate plus 3% per annum plus additional
lump-sum interest of 15% of each borrowing, payable at maturity. Repayment of
principal and interest is based on a three year amortization schedule.
During the nine months ended September 30, 1997 and 1996, VidaMed consumed cash
in operations of $10,952,000 and $9,372,000, respectively. The changes in net
cash used in operations were mainly attributable to increased accounts
receivable resulting from increased product sales and sales and marketing
expenses associated with the product launch of the VidaMed TUNA System in the
United States.
Page 10 of 16
<PAGE>
The Company moved in July 1997 to a 35,000 square foot facility in Fremont, CA.
The Company incurred approximately $1.0 million in capital expenditures with the
move to the new facility in the third quarter.
Although VidaMed believes that its current capital resources and cash generated
from the sale of products will be sufficient to meet the Company's operating and
capital requirements through the next twelve months, there can be no assurance
that the Company will not require additional financing within this time frame.
There can be no assurance that additional financing, if required, will be
available on satisfactory terms or at all. In any event, VidaMed anticipates in
the future that it may seek to raise additional funds through bank facilities,
debt or equity offerings or other sources of capital. VidaMed's future liquidity
and capital requirements will depend on numerous other factors, including
progress of clinical trials, actions related to regulatory and reimbursement
matters, and the extent to which the TUNA system gains market acceptance.
Restructuring Accrual
In September 1997, VidaMed announced a restructuring program designed to reduce
costs and improve operating efficiencies by closing the company's U.K.
manufacturing facility. The company expects to incur approximately $1.7 million
in cash outlays, primarily over the next twelve months. See also Footnote 5.
Page 11 of 16
<PAGE>
VIDAMED, INC.
PART II: OTHER INFORMATION
Item 1. Legal Proceedings
None
Item 2. Changes in Securities
See page 14.
Item 3. Defaults upon Senior Securities
None
Item 4. Submission of Matters to a Vote of Security Holders
None
Item 5. Other Information
None
Item 6. Exhibits and Reports on Form 8-K
a) Exhibits
(27.1) Financial Data Schedule
b) Reports on Form 8-K. No reports on Form 8-K were filed
during the quarter ended September 30, 1997.
Page 12 of 16
<PAGE>
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto.
VIDAMED, INC.
Date: November 7, 1997 By: /s/ James A. Heisch
--------------------- ------------------------
James A. Heisch
President, Chief Executive Officer
Date: November 7, 1997 By: /s/ Richard D. Brounstein
--------------------- ------------------------------
Richard D. Brounstein
VP Finance, Chief Financial Officer
(Principal Financial and Accounting
Officer)
Page 13 of 16
<PAGE>
PART II. OTHER INFORMATION
Item 2. CHANGES IN SECURITIES
In the third quarter of 1997 the Company issued 104,260 shares and closed out
the $10 million equity line with a European investment bank.
During the third quarter of 1997 the Company completed a private placement with
certain investors in the amount of $11,702,000 in exchange for 2,587,351 shares
of common stock.
Page 14 of 16
<PAGE>
INDEX TO EXHIBITS
EXHIBIT
NUMBER DESCRIPTION
27.1 Financial Data Schedule
Page 15 of 16
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JUL-01-1997
<PERIOD-END> SEP-30-1997
<CASH> 13,517
<SECURITIES> 0
<RECEIVABLES> 3,823
<ALLOWANCES> 466
<INVENTORY> 1,604
<CURRENT-ASSETS> 19,499
<PP&E> 7,089
<DEPRECIATION> 3,619
<TOTAL-ASSETS> 23,200
<CURRENT-LIABILITIES> 10,287
<BONDS> 666
0
0
<COMMON> 15
<OTHER-SE> 12,232
<TOTAL-LIABILITY-AND-EQUITY> 23,200
<SALES> 7,164
<TOTAL-REVENUES> 7,814
<CGS> 6,354
<TOTAL-COSTS> 6,354
<OTHER-EXPENSES> (86)
<LOSS-PROVISION> 367
<INTEREST-EXPENSE> 378
<INCOME-PRETAX> (13,345)
<INCOME-TAX> 11
<INCOME-CONTINUING> (13,356)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (13,356)
<EPS-PRIMARY> (1.11)
<EPS-DILUTED> (1.11)
</TABLE>
